H.C. Wainwright analyst Andres Maldonado initiated coverage of Day One Biopharmaceuticals with a Buy rating and $35 price target. The company continues to garner an impressive clinical profile in BRAF-associated relapsed pediatric low-grade glioma where there are no approved therapies or standard of care, Maldonado tells investors in a research note. The analyst is positive ahead of FIREFLY-1’s topline data in Q1 of 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DAWN:
- Day One Biopharmaceuticals initiated with a Buy at Needham
- Day One Biopharmaceuticals initiated with a Buy at Goldman Sachs
- Day One Biopharmaceuticals initiated with a Buy, $34 price target at BofA
- Day One Biopharmaceuticals initiated with a Buy at BofA
- Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
